search icon
tovx-img

Theriva Biologics Inc., Common Stock

TOVX

ASQ

$0.455

-$0.01

(-2.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.57M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
152.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.15
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.41 L
$7.25 H
$0.455

About Theriva Biologics Inc., Common Stock

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTOVXSectorS&P500
1-Week Return-18.75%-1.91%-1.87%
1-Month Return-68.18%-3.82%8.93%
3-Month Return-70.07%-11.56%-2.39%
6-Month Return-65%-10.21%-2.41%
1-Year Return-94.48%-9.91%10.88%
3-Year Return-99.17%-0.28%46.93%
5-Year Return-99.46%31.29%94.89%
10-Year Return-100%75.9%177.5%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue201.00K87.00K268.00K135.00K137.00K[{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":32.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.37,"profit":true},{"date":"2024-12-31","value":51.12,"profit":true}]
Gross Profit(201.00K)(87.00K)(268.00K)(135.00K)-[{"date":"2020-12-31","value":-20100000,"profit":false},{"date":"2021-12-31","value":-8700000,"profit":false},{"date":"2022-12-31","value":-26800000,"profit":false},{"date":"2023-12-31","value":-13500000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses10.16M14.27M21.58M21.43M19.43M[{"date":"2020-12-31","value":47.08,"profit":true},{"date":"2021-12-31","value":66.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.3,"profit":true},{"date":"2024-12-31","value":90.02,"profit":true}]
Operating Income(10.16M)(14.27M)(21.58M)(21.43M)(26.35M)[{"date":"2020-12-31","value":-1016000000,"profit":false},{"date":"2021-12-31","value":-1427400000,"profit":false},{"date":"2022-12-31","value":-2158100000,"profit":false},{"date":"2023-12-31","value":-2143100000,"profit":false},{"date":"2024-12-31","value":-2634600000,"profit":false}]
Total Non-Operating Income/Expense88.00K12.00K983.00K2.88M1.39M[{"date":"2020-12-31","value":3.05,"profit":true},{"date":"2021-12-31","value":0.42,"profit":true},{"date":"2022-12-31","value":34.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":48.2,"profit":true}]
Pre-Tax Income(10.12M)(14.27M)(21.11M)(19.99M)(25.65M)[{"date":"2020-12-31","value":-1011600000,"profit":false},{"date":"2021-12-31","value":-1426800000,"profit":false},{"date":"2022-12-31","value":-2111000000,"profit":false},{"date":"2023-12-31","value":-1998900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}]
Income Taxes(117.00K)(94.00K)(1.43M)(1.64M)-[{"date":"2020-12-31","value":-11700000,"profit":false},{"date":"2021-12-31","value":-9400000,"profit":false},{"date":"2022-12-31","value":-142500000,"profit":false},{"date":"2023-12-31","value":-164000000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(10.00M)(14.17M)(19.68M)(18.35M)-[{"date":"2020-12-31","value":-999900000,"profit":false},{"date":"2021-12-31","value":-1417400000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1834900000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(10.12M)(14.27M)(19.68M)(19.31M)(25.65M)[{"date":"2020-12-31","value":-1011600000,"profit":false},{"date":"2021-12-31","value":-1426800000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1930900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(10.00M)(14.17M)(19.68M)(18.35M)(25.65M)[{"date":"2020-12-31","value":-999900000,"profit":false},{"date":"2021-12-31","value":-1417400000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1834900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}]
EPS (Diluted)(6.10)(2.10)(1.27)(1.17)(29.35)[{"date":"2020-12-31","value":-610,"profit":false},{"date":"2021-12-31","value":-210,"profit":false},{"date":"2022-12-31","value":-127,"profit":false},{"date":"2023-12-31","value":-117,"profit":false},{"date":"2024-12-31","value":-2935.07,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TOVX
Cash Ratio 1.23
Current Ratio 1.53

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TOVX
ROA (LTM) -27.43%
ROE (LTM) -100.01%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TOVX
Debt Ratio Lower is generally better. Negative is bad. 0.52
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.48

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TOVX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.24
Price/FCF NM
EV/R 0.00
EV/Ebitda 1.72

FAQs

What is Theriva Biologics Inc. share price today?

Theriva Biologics Inc. (TOVX) share price today is $0.455

Can Indians buy Theriva Biologics Inc. shares?

Yes, Indians can buy shares of Theriva Biologics Inc. (TOVX) on Vested. To buy Theriva Biologics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TOVX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Theriva Biologics Inc. be purchased?

Yes, you can purchase fractional shares of Theriva Biologics Inc. (TOVX) via the Vested app. You can start investing in Theriva Biologics Inc. (TOVX) with a minimum investment of $1.

How to invest in Theriva Biologics Inc. shares from India?

You can invest in shares of Theriva Biologics Inc. (TOVX) via Vested in three simple steps:

  • Click on Sign Up or Invest in TOVX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Theriva Biologics Inc. shares
What is Theriva Biologics Inc. 52-week high and low stock price?

The 52-week high price of Theriva Biologics Inc. (TOVX) is $7.25. The 52-week low price of Theriva Biologics Inc. (TOVX) is $0.41.

What is Theriva Biologics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Theriva Biologics Inc. (TOVX) is 0.24

What is the Market Cap of Theriva Biologics Inc.?

The market capitalization of Theriva Biologics Inc. (TOVX) is $4.57M

What is Theriva Biologics Inc.’s stock symbol?

The stock symbol (or ticker) of Theriva Biologics Inc. is TOVX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top